GH Secretagogues: Tesamorelin vs CJC-1295 vs Sermorelin vs Ipamorelin
Growth hormone secretagogues are among the most popular peptides in the optimization space, but they differ significantly in mechanism, evidence base, FDA status, and clinical profile. Tesamorelin and Sermorelin are both GHRH analogs that stimulate GH release through the hypothalamic pathway, while Ipamorelin is a ghrelin-mimetic secretagogue, and CJC-1295 is a modified GHRH analog with an extended half-life. Understanding these distinctions is essential for informed conversations with your clinician about which approach best fits your goals.
Tesamorelin
An FDA-approved GHRH analog used to reduce visceral fat in HIV-associated lipodystrophy.
CJC-1295
A growth hormone-releasing hormone analog that stimulates the pituitary gland to produce more growth hormone.
Sermorelin
A growth hormone-releasing hormone analog that was previously FDA-approved for diagnosing GH deficiency in children.
Ipamorelin
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.
| Category | Tesamorelin | CJC-1295 | Sermorelin | Ipamorelin |
|---|---|---|---|---|
| Drug Class | GHRH analog (44 amino acids) | Modified GHRH analog (29 aa) with DAC | GHRH analog (29 amino acids) | Ghrelin-mimetic GH secretagogue (5 aa) |
| Primary Mechanism | Binds GHRH receptor on pituitary somatotrophs | Binds GHRH receptor; DAC extends half-life via albumin binding | Binds GHRH receptor, mimics natural GHRH | Binds ghrelin/GHS receptor (GHS-R1a) on pituitary |
| FDA Status | FDA-approved (Egrifta®) for HIV lipodystrophy | Not FDA-approved; available via compounding | Previously FDA-approved (Geref®), now discontinued | Not FDA-approved; available via compounding |
| Evidence Level | Strong — multiple Phase III RCTs | Moderate — human PK/PD data, limited clinical trials | Moderate — historical clinical use, some RCTs | Moderate — Phase II data, well-characterized PK |
| Half-Life | 26 minutes (requires daily dosing) | ~8 days (with DAC); ~30 min without DAC | 11–16 minutes (requires daily dosing) | ~2 hours (longer than natural ghrelin) |
| GH Pulse Pattern | Amplifies natural pulsatile release | With DAC: sustained GH elevation; without DAC: pulsatile | Mimics natural pulsatile GH release | Stimulates discrete GH pulses |
| Effect on Cortisol | Minimal | Minimal | Minimal | No significant cortisol increase (selective) |
| Effect on Prolactin | Minimal | Minimal | Minimal | No significant prolactin increase (selective) |
| Effect on Hunger/Ghrelin | Minimal appetite effect | Minimal appetite effect | Minimal appetite effect | Mild transient hunger possible (ghrelin pathway) |
| Key Clinical Benefits | Visceral fat reduction (proven), improved lipid profile, body composition | Sustained GH/IGF-1 elevation, body composition, recovery | GH restoration, anti-aging, sleep quality, body composition | Clean GH pulse, sleep quality, recovery, body composition |
| Common Pairing | Often used as monotherapy | Frequently paired with Ipamorelin for synergy | Sometimes paired with Ipamorelin or MK-677 | Frequently paired with CJC-1295 (no DAC) for synergy |
| Administration | Subcutaneous injection, daily | Subcutaneous injection, 2–3x/week (with DAC) or daily (no DAC) | Subcutaneous injection, daily (typically before bed) | Subcutaneous injection, daily (typically before bed) |
| Safety Profile | Well-studied; injection site reactions, arthralgia, edema | Moderate data; injection site reactions, water retention, headache | Moderate data; facial flushing, injection site pain, headache | Moderate data; well-tolerated, mild injection site reactions |
| Ideal Candidate | Those with visceral adiposity or seeking FDA-backed GH therapy | Those wanting sustained GH elevation with less frequent dosing | Those seeking physiologic GH restoration with historical clinical precedent | Those wanting selective, clean GH pulses without cortisol/prolactin effects |
Summary
The GH secretagogue landscape offers distinct options depending on your goals and risk tolerance. Tesamorelin stands apart as the only FDA-approved option, with robust Phase III data specifically for visceral fat reduction — making it the strongest evidence-based choice. CJC-1295 with DAC offers convenience through less frequent dosing and sustained GH elevation, though the non-pulsatile pattern is debated among clinicians. Sermorelin has the longest clinical history and mimics natural GH physiology closely, but its short half-life requires daily injections. Ipamorelin is prized for its selectivity — it stimulates GH without raising cortisol, prolactin, or aldosterone, making it one of the cleanest secretagogues available. The CJC-1295 (no DAC) + Ipamorelin combination is arguably the most popular pairing in the peptide space, as the GHRH analog and ghrelin-mimetic work through complementary pathways to amplify GH release synergistically. Your clinician can help determine which approach — or which combination — best aligns with your specific health goals, lab values, and medical history.
These peptides are often used together. See our stack profiles for combination details.